Targeting Lewis Y (Le(y)) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levels.
Lee M Krug, Daniel T Milton, Achim A Jungbluth, Lin-Chi Chen, Emilio Quaia, Neeta Pandit-Taskar, Andrew Nagel, Jessica Jones, Mark G Kris, Ronald Finn, Peter Smith-Jones, Andrew M Scott, Lloyd Old, Chaitanya Divgi
Journal of Thoracic Oncology | Published : 2007
INTRODUCTION: Lewis Y (Le(y)) is a blood group antigen with robust expression on the surface of epithelial tumors, including small cell lung cancer (SCLC), making it a potential target for antibody-based immunotherapy. 3S193, an immunoglobulin G3 monoclonal antibody, has demonstrated superior specificity, affinity, and cytotoxicity over other anti-Le(y) antibodies. A phase I trial of humanized 3S193 (hu3S193) with dosing up to 40 mg/m2 demonstrated tumor targeting without serious toxicities or the development of human anti-human antibodies. METHODS: We tested the targeting and pharmacokinetics of hu3S193 in patients with SCLC. Eligibility required progressive SCLC treated with up to three pr..View full abstract